Improved development of somatic cell cloned bovine embryos by a mammary gland epithelia cells in vitro model

XiaoYing He,LiBing Ma,Xiao-ning He,Wan-tong Si,Yue-Mao Zheng 대한수의학회 2016 Journal of Veterinary Science Vol.17 No.2

Previous studies have established a bovine mammary gland epithelia cells in vitro model by the adenovirus-mediated telomerase (hTERT-bMGEs). The present study was conducted to confirm whether hTERT-bMGEs were effective target cells to improve the efficiency of transgenic expression and somatic cell nuclear transfer (SCNT). To accomplish this, a mammary-specific vector encoding human lysozyme and green fluorescent protein was used to verify the transgenic efficiency of hTERT-bMGEs, and untreated bovine mammary gland epithelial cells (bMGEs) were used as a control group. The results showed that the hTERT-bMGEs group had much higher transgenic efficiency and protein expression than the bMGEs group. Furthermore, the nontransgenic and transgenic hTERT-bMGEs were used as donor cells to evaluate the efficiency of SCNT. There were no significant differences in rates of cleavage or blastocysts or hatched blastocysts of cloned embryos from nontransgenic hTERT-bMGEs at passage 18 and 28 groups (82.8% vs. 81.9%, 28.6% vs. 24.8%, 58.6% vs. 55.3%, respectively) and the transgenic group (80.8%, 26.5% and 53.4%); however, they were significantly higher than the bMGEs group (71.2%, 12.8% and 14.8%), (p < 0.05). We confirmed that hTERT-bMGEs could serve as effective target cells for improving development of somatic cell cloned cattle embryos.

Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer

Libing Xiang,Yunxia Tu,Tiancong He,Xuxia Shen,Ziting Li,Xiaohua Wu,Huijuan Yang 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.6

Objective: Distal pancreatectomy with splenectomy may be required for optimalcytoreductive surgery in patients with epithelial ovarian cancer (EOC) metastasized tosplenic hilum. This study evaluates the morbidity and treatment outcomes of the uncommonprocedure in the management of advanced or recurrent EOC. Methods: This study recruited 18 patients who underwent distal pancreatectomy withsplenectomy during cytoreductive surgery of EOC. Their clinicopathological characteristicsand follow-up data were retrospectively analyzed. Results: All tumors were confirmed as high-grade serous carcinomas. The mediandiameter of metastatic tumors located in splenic hilum was 3.5 cm (range, 1 to 10 cm). Optimal cytoreduction was achieved in all patients. Eight patients (44.4%) sufferedfrom postoperative complications. The morbidity associated with distal pancreatectomyand splenectomy included pancreatic leakage (22.2%), encapsulated effusion in theleft upper quadrant (11.1%), intra-abdominal infection (11.1%), pleural effusion withor without pulmonary atelectasis (11.1%), intestinal obstruction (5.6%), pneumonia(5.6%), postoperative hemorrhage (5.6%), and pancreatic pseudocyst (5.6%). Therewas no perioperative mortality. The majority of complications were treated successfullywith conservative management. During the median follow-up duration of 25 months,nine patients experienced recurrence, and three patients died of the disease. The 2-yearprogression-free survival and overall survival were 40.2% and 84.8%, respectively. Conclusion: The inclusion of distal pancreatectomy with splenectomy as part ofcytoreduction for the management of ovarian cancer was associated with high morbidity;however, the majority of complications could be managed with conservative therapy.

Somatic cell reprogrammed by oocyte: process and barricade

LiBing Ma,XiaoYing He,FengMei Wang,Teng Cheng,XiYu Liu 한국통합생물학회 2014 Animal cells and systems Vol.18 No.3

Somatic cell nuclear transfer (SCNT) is a technology in which a somatic nucleus is transferred into thecytoplasm of a matured oocyte – reconstructed embryos have the capacity to develop to term. Why somaticcells can be reprogrammed by oocytes – the answer for this question must exist in the cytoplasm of maturedoocytes. In this review, totipotent characters of matured oocytes were discussed, which may confer maturedoocytes with the capacity to reprogram somatic nucleus. Moreover, the procedure of SCNT also makes apossibility for somatic nucleus to be reprogrammed by oocytes. Compared with fertilized embryos, embryosderived from SCNT exhibit low developmental ability; the barricades in reprogramming process and theirpossible reasons were also discussed. This review maybe can benefit the mechanism research of SCNTtechnology and can make contribution for improving the efficiency of this technology.

Mutational analysis of KRAS and its clinical implications in cervical cancer patients

Wei Jiang,Libing Xiang,Xuan Pei,Tiancong He,Xuxia Shen,Xiaohua Wu,Huijuan Yang 대한부인종양학회 2018 Journal of Gynecologic Oncology Vol.29 No.1

Objective: The predictive and prognostic role of KRAS mutations in cervical cancer remainsinconclusive. The aim of this study was to explore the clinicopathological and prognosticrelevance of KRAS mutations in invasive cervical cancers (ICC). Methods: Reverse transcription polymerase chain reaction (PCR) and Sanger sequencingwere employed to detect KRAS mutations in 876 ICC patients. Quantitative real-time PCR wasused to detect human papillomavirus (HPV) 16 and HPV 18. Results: Non-synonymous mutations of KRAS were identified in 30 (3.4%) patients. Thesemutations were more common in non-squamous cell carcinoma than in squamous cellcarcinoma (SCC) (8.2% vs. 2.2%, respectively, p<0.001) and were associated with HPV 18infection (p=0.003). The prevalence of mutations was highest (18.2%) in the uncommonhistological subtypes followed by adenocarcinoma (AC, 7.3%) and adenosquamouscarcinoma (ASC, 5.8%). During the median follow-up of 55 months, compared to patientswith wild-type KRAS, a greater percentage of patients with mutant KRAS relapsed (20.0%vs. 42.9%, respectively, p=0.007). The 3-year relapse-free survival was poorer in patientswith mutant KRAS than in patients without KRAS mutations (57.1% vs. 81.9%, respectively,p=0.001). Furthermore, the multivariate analysis showed that the presence of a KRASmutation was an independent predictor for disease recurrence (hazard ratio [HR]=2.064;95% confidence interval [CI]=1.125–3.787; p=0.019). Conclusion: KRAS mutations were predominant in non-SCCs of the cervix and wereassociated with HPV 18 infection. A combination of KRAS mutation detection andHPV genotyping would be useful in identifying patient with poor prognosis for furtherinterventions.

Antimicrobial activity of a conjugated polymer with cationic backbone

Xu, Qingling,He, Ping,Wang, Jianwu,Chen, Hui,Lv, Fengting,Liu, Libing,Wang, Shu,Yoon, Juyoung Elsevier 2019 Dyes and pigments Vol.160 No.-

<P><B>Abstract</B></P> <P>Owing to the misuse of antibiotics and slow development of new drugs, antibiotic-resistant pathogens have become a serious threat to human health. With the aim of developing new antimicrobial agents, we designed and synthesized a new conjugated polymer (<B>PFPhim</B>), which possesses an imidazolium containing backbone. The cationic backbone enables it to strongly interact with bacterial membrane leading to an antimicrobial ability that is more potent than that of a conjugated polymer containing a neutral backbone. <B>PFPhim</B> also displays strong photodynamic antimicrobial activity.</P> <P><B>Highlights</B></P> <P> <UL> <LI> A conjugated polymer possessing imidazolium in the backbone was synthesized. </LI> <LI> The polymer shows good an bacterial ability over Ampr E. Coli in darkness. </LI> <LI> The polymer also displays strong photodynamic antimicrobial activity. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>

Hyperbranched Electroactive Azo Polyamide Based on Oligoaniline: Synthesis, Characterization, and Dielectric Properties

Xiaoteng Jia,Ce Wang,Danming Chao,Libing He,Hongtao Liu,Tian Zheng,Chengcheng Zhang 한국고분자학회 2011 Macromolecular Research Vol.19 No.11

A novel hyperbranched electroactive azo polyamide containing oligoaniline was synthesized by oxidative coupling polymerization. The detailed characteristics of the obtained polyamide were systematically studied by Fourier transform infrared (FTIR) spectra, nuclear magnetic resonance (^1H NMR) spectroscopy, and gel permeation chromatography (GPC). The thermogravimetric analysis (TGA) revealed a good thermal resistance of the polymer. The photoisomerization process and doping process of the polymer were monitored with ultraviolet-visible spectroscopy. Further, the electrochemical behavior of the polymer was explored by cyclic voltammogram (CV), and the mechanism of electrochemical oxidation process was studied in detail. The polymer in the HCl-doped form possessed much higher dielectric constants compared with that of the similar linear polymer reported before, mainly due to the highly branched three-dimensional molecular architecture and the high content of oligoaniline segments.

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

Ting-Yan Shi,Sheng Yin,Jianqing Zhu,Ping Zhang,Jihong Liu,Libing Xiang,Yaping Zhu,Sufang Wu,Xiaojun Chen,Xipeng Wang,Yin-Cheng Teng,Tao Zhu,Aijun Yu,Yingli Zhang,Yanling Feng,He Huang,Wei Bao,Yanli Li 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.3

Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Moreover, poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance now has been a standard care for platinum sensitive relapsed OC. To our knowledge, no published or ongoing trial is trying to answer the question if patient can benefit from a potentially complete resection combined with PARPi maintenance in OC patients with secondary recurrence. Methods: SOC-3 is a multi-center, open, randomized, controlled, phase II trial of SCR followed by chemotherapy and niraparib maintenance vs chemotherapy and niraparib maintenance in patients with platinum-sensitive second relapsed OC who never received SCR at recurrence. To guarantee surgical quality, if the sites had no experience of participating in any OC-related surgical trials, the number of recurrent lesions evaluated by central-reviewed positron emission tomography–computed tomography image shouldn't be more than 3. Eligible patients are randomly assigned in a 1:1 ratio to receive either SCR followed by 6 cycles of platinum-based chemotherapy and niraparib maintenance or 6 cycles of platinum-based chemotherapy and niraparib maintenance alone. Patients who undergo at least 4 cycles of chemotherapy and must be, in the opinion of the investigator, without disease progression, will be assigned niraparib maintenance. Major inclusion criteria are secondary relapsed OC with a platinum-free interval of no less than 6 months and a possibly complete resection. Major exclusion criteria are borderline tumors and non-epithelial ovarian malignancies, received debulking surgery at recurrence and impossible to complete resection. The sample size is 96 patients. Primary endpoint is 12-month non-progression rate. Trial Registration: ClinicalTrials.gov Identifier: NCT03983226